Effects of miR-144 on the sensitivity of human anaplastic thyroid carcinoma cells to cisplatin by autophagy regulation

Liu, Jing; Feng, Liguo; Zhang, Haitao; Zhang, Jin; Zhang, Yanyan; Li, Shujing; Qin, Long; Yang, Ziyao; Xiong, Jian-Xia

doi:10.1080/15384047.2018.1433502

Cited by 25 publications

(16 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In terms of chemoresistance, miR-144 reversed 5-FU and imatinib resistance respectively in HCC ( 461 ) and leukemia ( 462 ). In addition, miR-144 might promote cisplatin sensitivity in prostate cancer ( 463 ) and in thyroid carcinoma ( 464 ). Whereas miR-144-3p contributed to sunitinib resistance in RCC by targeting ARID1A, a cancer gene involved in chromatin remodeling ( 465 ).…”

Section: Drugs/non-coding Rnas Subnetworkmentioning

confidence: 99%

The Network of Non-coding RNAs in Cancer Drug Resistance

et al. 2018

View full text Add to dashboard Cite

Non-coding RNAs (ncRNAs) have been implicated in most cellular functions. The disruption of their function through somatic mutations, genomic imprinting, transcriptional and post-transcriptional regulation, plays an ever-increasing role in cancer development. ncRNAs, including notorious microRNAs, have been thus proposed to function as tumor suppressors or oncogenes, often in a context-dependent fashion. In parallel, ncRNAs with altered expression in cancer have been reported to exert a key role in determining drug sensitivity or restoring drug responsiveness in resistant cells. Acquisition of resistance to anti-cancer drugs is a major hindrance to effective chemotherapy and is one of the most important causes of relapse and mortality in cancer patients. For these reasons, non-coding RNAs have become recent focuses as prognostic agents and modifiers of chemo-sensitivity. This review starts with a brief outline of the role of most studied non-coding RNAs in cancer and then highlights the modulation of cancer drug resistance via known ncRNAs based mechanisms. We identified from literature 388 ncRNA-drugs interactions and analyzed them using an unsupervised approach. Essentially, we performed a network analysis of the non-coding RNAs with direct relations with cancer drugs. Within such a machine-learning framework we detected the most representative ncRNAs-drug associations and groups. We finally discussed the higher integration of the drug-ncRNA clusters with the goal of disentangling effectors from downstream effects and further clarify the involvement of ncRNAs in the cellular mechanisms underlying resistance to cancer treatments.

show abstract

Section: Drugs/non-coding Rnas Subnetworkmentioning

confidence: 99%

The Network of Non-coding RNAs in Cancer Drug Resistance

et al. 2018

View full text Add to dashboard Cite

show abstract

“…For example, the miR-34c-induced silencing of MC3T3-E1 reduces the inhibitory effect of vaspin on osteoblast differentiation (23); furthermore, miRNA (miR)-433-3p can regulate osteoblastic differentiation by targeting Dickkopf-1 ( DKK1 ) (24). As an important miRNA, miR-144 is known to be involved in the occurrence and development of various human diseases, including ovarian cancer (25), cervical cancer (26) and anaplastic thyroid carcinoma (27). For example, miR-144 acts as a tumor suppressor in osteosarcoma by inhibiting cell proliferation and inducing apoptosis (28).…”

Section: Introductionmentioning

confidence: 99%

miR‑144 promotes the proliferation and differentiation of bone mesenchymal stem cells by downregulating the expression of SFRP1

Tang

Huang

et al. 2019

Mol Med Report

View full text Add to dashboard Cite

Osteoporosis (OP) seriously affects the health and quality of life of elderly individuals and postmenopausal women, and the need to identify drugs that can prevent or treat OP remains urgent. Recently, several miRNAs have been reported to be involved in the differentiation of mesenchymal stem cells and osteoblasts; however, the role of miRNA (miR)-144 in regulating OP remains to be elucidated. In the present study, the expression levels of miR-144, secreted frizzled-related protein 1 (Sfrp1) and TNF-α in clinical samples were detected by the reverse transcription-quantitative polymerase chain reaction analysis and ELISA, respectively. 5-Ethynyl-2′-deoxyuridine staining, Hoechst 33258 staining, flow cytometry, a clone formation assay and Alizarin red staining were used to assess the effects of miR-144 combined with or without Sfrp1 small interfering RNA on the proliferation, apoptosis and osteoblastic differentiation of primary mesenchymal stem cells isolated from rats. Western blot assays were performed to assess the relevant mechanisms, and a dual luciferase reporter assay was used to detect the interaction between miR-144 and Sfrp1. The results showed that the levels of miR-144, Sfrp1 and TNF-α in clinical serum samples obtained from patients with postmenopausal OP were higher than those in serum samples obtained from postmenopausal women with normal bone density. There was a significant positive correlation between miR-144 and Sfrp1. Functional experiments demonstrated that miR-144 promoted proliferation, inhibited apoptosis and induced the osteoblastic differentiation of bone marrow-derived mesenchymal stem cells by targeting Sfrp1 . It was also shown that miR-144 may help regulate OP by activating the Wnt/β-catenin pathway. These data suggest miR-144 as a novel target for preventing and treating OP.

show abstract

“…In cervical cancer cells, miR-144 reversed resistance to cisplatin via promoting cell apoptosis and inhibiting invasion through targeting of LIM homeobox 2 (LHX2) [104]. In addition to all of that, enhancing miR-144 expression could remarkably sensitize anaplastic thyroid carcinoma (ATC) cells to cisplatin through suppressing transforming growth factor (TGF)-α [105]. TGF-α is an epidermal growth factor (EGF)-related protein, and is highly expressed in most kinds of thyroid carcinomas.…”

Section: Microrna-144 and Cancer Treatmentsmentioning

confidence: 99%

MicroRNA-144: A novel biological marker and potential therapeutic target in human solid cancers

Zhou

Hongwu

et al. 2020

J. Cancer

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are a class of small non-coding RNAs that negatively regulate gene expression at the post-transcriptional level. It has been reported that microRNA-144 (miR-144) is highly conserved and can combine complementarily with the 3'-UTRs of target gene mRNAs to inhibit mRNA translation or promote targeted mRNA degradation. MiR-144 is abnormally expressed and has been identified as a tumor suppressor in many types of solid tumors. Increasing evidence supports a crucial role for miR-144 in modulating physiopathologic processes, such as proliferation, apoptosis, invasion, migration and angiogenesis in different tumor cells. Apart from these functions, miR-144 can also affect drug sensitivity, cancer treatment and patient prognosis. In this review, we summarize the biological functions of miR-144, its direct targets and the important signal pathways through which it acts in relation to various tumors. We also discuss the role of miR-144 in tumor biology and its clinical significance in detail and offer novel insights into molecular targeting therapy for human cancers.

show abstract

Effects of miR-144 on the sensitivity of human anaplastic thyroid carcinoma cells to cisplatin by autophagy regulation

Abstract: MiR-144 could inhibit autophagy of ATC cells by down-regulating TGF-α, enhancing the cisplatin-sensitivity of ATC cells.

Cited by 25 publications

References 51 publications

The Network of Non-coding RNAs in Cancer Drug Resistance

The Network of Non-coding RNAs in Cancer Drug Resistance

miR‑144 promotes the proliferation and differentiation of bone mesenchymal stem cells by downregulating the expression of SFRP1

MicroRNA-144: A novel biological marker and potential therapeutic target in human solid cancers

Contact Info

Product

Resources

About